MAP2K1 and cardiofaciocutaneous syndrome: The majority of the cancer- and CFC-associated variants in MEK1/2 occur at the interface of the auto-inhibitory region, e.g. MEK2K57N, and the kinase domain, e.g. MEK1Y130C and MEK2E203K (Table 1; Fig. S1).